The clinical predictor of antitumor efficacy of cetuximab based regimen in first-line therapy to unresectable metastatic colorectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H. Tanioka
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H. Tanioka1, T. Nagasaka2, M. Asano1, K. Ikeda3, R. Yoshida3, N. Waki3, M. Ishizaki3, K. Yamashita3
  • 1Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan, /
  • 2Department of Digestive Surgery, Okayama University Hospital, Okayama, Japan, /
  • 3Department of Surgery, Okayama Rosai Hospital, Okayama, Japan, /

Abstract

Existence of RAS mutation used to predict response of anti-EGFR therapies in patients with metastatic colorectal cancer (mCRC). In this retrospective study, we investigated the other predictive or prognostic clinical characteristics for cetuximab based regimen in first-line therapy to unresectable mCRC patients.